Navigation Links
Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
Date:7/22/2008

- Systemic treatment with chemotherapy and pegylated enzyme produces

significantly enhanced survival compared to chemotherapy alone -

- Pegylated enzyme well tolerated -

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the presentation of positive pre-clinical animal efficacy data for its pegylated-rHuPH20 enzyme (PEGPH20) at the American Association for Cancer Research (AACR) Translational Cancer Medicine meeting in Monterey, CA. The study showed that treatment of hormone resistant human prostate cancer in tumor bearing mouse models with intravenous PEGPH20 in combination with the chemotherapeutic drugs, docetaxel (Taxotere(R)) or liposomal doxorubicin (Doxil(R)) resulted in a substantial increase in anti-tumor activity. The docetaxel combination treatment demonstrated significantly enhanced survival compared to treatment with the chemotherapeutic agent alone. The effects of PEGPH20 were selective to prostate tumors producing hyaluronan (HA), consistent with the selective reduction of tumor interstitial fluid pressure (IFP). Treatment with PEGPH20 was well tolerated in non tumor-bearing mice without significant increases in neutropenia (depletion of neutrophils, a type of white blood cell) compared to chemotherapy alone.

"These findings clearly demonstrate the activity of our long acting PEGPH20 enzyme candidate against HA-rich tumors in combination with chemotherapy," said Gregory Frost, PhD, Halozyme's Vice President and Chief Scientific Officer. "By targeting tumors that overproduce the HA matrix component, PEGPH20 may selectively att
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
2. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
3. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
6. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
7. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
8. Velcura Therapeutics, Inc. Adds William Brinkerhoff to its Board of Directors
9. PTC Therapeutics Announces $25 Million Award From Cystic Fibrosis Foundation Therapeutics for Development of PTC124
10. Echo Therapeutics Announces Publication of Positive Clinical Data for its Symphony Transdermal Continuous Glucose Monitoring System in Journal of Diabetes Science and Technology
11. Nile Therapeutics Announces Dosing in Phase IIa Study of CD-NP in Heart Failure Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Regulatory and Reimbursement Landscape Poland " an essential ... in the healthcare market and provides insights into ... Most importantly, the report provides valuable insights into ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... ... , ... , , , ... ...
... , ... ... ... ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 2Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 3Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 4Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 2An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 3An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 4An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 6
(Date:8/28/2014)... 29, 2014 Top10BestSEOHosting.com has recently ... that FatCow, Hostgator and Bluehost are the best ... ) has been working in the hosting industry ... is connected to multiple GB connections to ensure ... disruptions to customers’ websites. The great thing is ...
(Date:8/28/2014)... 28, 2014 Blood's Thicker Than Water is ... and family ties in the heart of the city. Raymond ... a story about how disrespect caused two families to collide ... streets. , The Yayo Boyz and the M.O.B. Boyz clash ... and local onlookers in a silent terror. "Guerrilla," AKA "Real," ...
(Date:8/28/2014)... Tempe, Ariz. (PRWEB) August 28, 2014 ... Force Impact Technologies , has been named one ... of the Year competition. , This is the fourth ... finalist in the competition. Jared Schoepf, co-founder of SafeSIPP, ... in 2013 and 2012, respectively. In 2011, ASU dominated ...
(Date:8/28/2014)... 2014 (HealthDay News) -- Arguments between parents may damage ... Parents in more than 200 families were asked ... the end of each day, mothers and fathers rated ... their children. On days when parents reported conflict ... children were also strained, according to the study recently ...
(Date:8/28/2014)... August 28, 2014 ABC television stars ... 49th MDA Show of Strength Telethon airing Sunday, Aug. ... to help raise funds and awareness to help save ... by muscle disease. , Viewers tuning into the 2014 ... heart-felt appeals and introductions from some of the network’s ...
Breaking Medicine News(10 mins):Health News:Best Suppliers of Affordable Hosting Products Introduced by Top10BestSEOHosting.com 2Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4
... for what doctors call a life-threatening malignant glioma , , ... Kennedy,s doctors said Monday that they had completed a ... , "I am pleased to report that Senator Kennedy,s ... Friedman said in a statement, the Boston Globe ...
... Alcan Global Pharmaceutical Packaging,part of Rio Tinto Alcan,s ... it will participate in an initiative sponsored by ... the context of World,Environment Day. The theme for ... Low,Carbon Economy", and will be celebrated on June ...
... The world,s largest spa tradeshow and conference, LAS ... Spa Conference (IECSC) Las Vegas will be held on ... Center. Professionals from around the,world will convene at the ... experience the latest products and services, and,learn about the ...
... Healthcare Advertising Marketing Awards, INDIANAPOLIS, June ... over 4,400,entries, the 25th Annual Healthcare Advertising ... Indianapolis and St. Vincent Hospital for its,creative ... Additionally, both entities won three silver (Total ...
... following event,announcement was released by the Association for ... Association for Professionals in Infection Control and Epidemiology,(APIC,s) ... WHEN:, Sunday - Thursday, June 15-19, 2008, ... 700 14th Street (Directions, http://www.denverconvention.com/about-directions.htm ), ...
... Animal Dermatology Clinic (ADC) - San,Diego announces ... the,American College of Veterinary Dermatology (ACVD)., Dr. ... degree,from the University of California, Davis in 2001. ... VCA Emergency Animal Hospital,and Referral Center in San ...
Cached Medicine News:Health News:Sen. Kennedy's Brain Tumor Surgery Called a 'Success' 2Health News:Sen. Kennedy's Brain Tumor Surgery Called a 'Success' 3Health News:Sen. Kennedy's Brain Tumor Surgery Called a 'Success' 4Health News:The second year of participation for Alcan Global Pharmaceutical Packaging in World Environment Day 2Health News:International Esthetics, Cosmetics & Spa Conference - Las Vegas 2Health News:International Esthetics, Cosmetics & Spa Conference - Las Vegas 3Health News:Publicis Indianapolis and St. Vincent Hospital Win the Gold 2Health News:Animal Dermatology Clinic - San Diego Announces Dr. Brett Wildermuth, DVM, Achieves Diplomate Status With the American College of Veterinary Dermatology 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: